Table 1. Patient demographics and hematopoietic cell collections.
| Parameter | Phase I (n = 45) | Expanded MTD cohort (n = 16) |
|---|---|---|
| Median age, y (range) | 46 (29–63) | 58 (35–64) |
| Sex, n (%) | ||
| Female | 40 (89) | 6 (38) |
| Male | 5 (11) | 10 (63) |
| Race, n (%) | ||
| White | 38 (84) | 14 (88) |
| Black | 3 (7) | 1 (6) |
| Hispanic | 3 (7) | 1 (6) |
| Other | 1 (2) | |
| Primary tumor type, patients, n (%) | ||
| Breast cancer | 29 (64) | |
| NHL | 8 (18) | 14 (88) |
| Low grade/indolent | 4 (9) | 3 (19) |
| Intermediate grade/aggressive | 4 (9) | 11 (69) |
| Hodgkin lymphoma | 0 | 2 (12) |
| Ovarian cancer | 7 (16) | |
| Testicular cancer | 1 (2) | |
| Hematopoietic cell source, n (%) | ||
| Bone marrow (no priming) Peripheral blood | 1 (2) | |
| Cyclophosphamide/taxol/G-CSF | 33 (73) | |
| Cyclophosphamide/etoposide/G-CSF | 7 (16) | 16 (100) |
| G-CSF | 2 (4) | |
| Both | ||
| Cyclophosphamide/taxol/G-CSF (PB) | 1 (2) | |
| G-CSF + GM-CSF (PB) | 1 (2) | |
| CD34+ cells/kg collected, ×106; median (range) | 4.01 (0.11–72.10) | 3.01 (2.05–8.48) |
Abbreviation: PB, peripheral blood.